Skip to content

"Tongdu Xingshen" acupuncture regulates the iron homeostasis pathway and improves vascularity Clinical studies of cognitive dysfunction

"Tongdu Xingshen" acupuncture regulates the iron homeostasis pathway and improves vascularity Clinical studies of cognitive dysfunction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072188
Enrollment
Unknown
Registered
2023-06-06
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular cognitive impairment

Interventions

Observation group:On the basis of conventional treatment, electroacupuncture is performed, once a day, each time for 30min, leave the needle for 1h, rest for 1 day a week, for a total of 4 weeks
Control group:Conventional basic treatment
Healthy control group:N/A

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for stroke (Western medicine diagnostic criteria refer to the "2019 Chinese Vascular Cognitive Impairment Diagnosis and Treatment Guidelines"; The diagnostic criteria of traditional Chinese medicine refer to the "Diagnosis, Differentiation and Efficacy Judgment Criteria for Vascular Dementia (for Research)" (2) There is a history of ischemic stroke confirmed by CT or MRI examination; (3) Cognitive impairment occurs after stroke, and cognitive dysfunction is clearly indicated after evaluation by the Mini-Mental Status Examination Scale (MMSE) and the Montreal Cognitive Assessment Scale (MoCA); (4) 1 month= course of disease = 2 years; No drugs to improve cognitive function were used prior to enrollment; (5) Consciousness is clear, vital signs are stable; (6)18 years old= age = 75 years.

Exclusion criteria

Exclusion criteria: (1) There are other diseases that can lead to cognitive impairment, such as intracranial mass lesions, brain trauma, arterial hemangioma, etc.; (2) Diseases accompanied by serious impact on cognitive examination, such as abnormal audiovisual function, mental abnormalities, etc.; (3) There was a history of significant cognitive decline or dementia before the onset of this disease; (4) Accompanied by other serious diseases such as immune diseases, endocrine diseases and abnormal liver and kidney function; (5) pregnant and lactating women; (6) Coagulation dysfunction and infection at the treatment site.

Design outcomes

Primary

MeasureTime frame
MMSE score;MoCA score;Clinical Dementia Rating;Serum iron; ferritin;Transferrin;Transferring receptor 1;Total iron binding strength;haemoglobin;Susceptibility-weighted imaging;

Secondary

MeasureTime frame
Improved Barthel index;

Countries

China

Contacts

Public ContactWumingli

The First Affiliated Hospital of Henan University of Chinese Medicine

wumingliyouxiang@163.com+86 135 2640 3147

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026